Skip Navigation

Alvogen’s subsidiary in Taiwan, Lotus Pharmaceuticals collects outstanding company award

25 July 2019

Robert Wessman, the CEO of the global pharmaceuticals company Alvogen and Chairman of its Asian subsidiary, Lotus Pharmaceuticals (“Lotus”), was very happy to pick up the Outstanding Company Award on the occasion of BIO Asia event on 25 July. Since Alvogen’s acquisition of Lotus in 2014, the company has transformed from a small Taiwanese company to a global pharmaceutical player, valued at over US$1 billion in the Taiwanese stock exchange.

Upon receiving the award, Lotus Chairman Robert Wessman was very keen to point out during his speech on the success of the Lotus/Alvogen venture that this award is the sweet result of the combined efforts of more than 1000 employees in Asia.

“We are delighted with the transformation of Lotus, where we have a clear focus on oncology products and complex generic pharmaceuticals that are delivered to patients around the world. Creating a business traded for over US$1 billion from such a small base is something we can all be very proud of,” Wessman added.

BIO Asia is a key event in the region, which combines conferences with exhibitions and this year involved delegates and companies from over 20 countries. The event was hosted in Taipei where the President of the Republic of China, Tsai Ing Wen, and CEO of BIO (Biotechnology Innovation Organization), James Greenwood, as well as the Chairman of BIO Taiwan, Johnsee Lee, were there to welcome the guests and confer the awards.